AbCellera Biologics Inc.
General ticker "ABCL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B (TTM average)
AbCellera Biologics Inc. follows the US Stock Market performance with the rate: 52.5%.
Estimated limits based on current volatility of 2.8%: low 10.71$, high 11.33$
Factors to consider:
- Total employees count: 562 (-6.3%) as of 2025
- US accounted for 9.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Financing risks, Product development failure, Supply chain disruptions, Regulatory and compliance, Litigation risks
- Current price 93.3% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.50$, 5.90$]
- 2026-12-31 to 2027-12-31 estimated range: [2.28$, 5.50$]
Financial Metrics affecting the ABCL estimates:
- Positive: with PPE of -7.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Interest expense per share per price, % of 0 <= 0
- Positive: 69.38 < Shareholder equity ratio, % of 71.26 <= 81.92
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Investing cash flow per share per price, % of 8.21 > 2.08
Short-term ABCL quotes
Long-term ABCL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $38.02MM | $28.83MM | $75.13MM |
| Operating Expenses | $275.23MM | $343.60MM | $292.23MM |
| Operating Income | $-237.21MM | $-314.77MM | $-217.10MM |
| Non-Operating Income | $63.18MM | $114.37MM | $39.51MM |
| R&D Expense | $175.66MM | $167.26MM | $186.83MM |
| Income(Loss) | $-174.03MM | $-200.40MM | $-177.59MM |
| Taxes | $-27.63MM | $-37.54MM | $-31.18MM |
| Net Income(Loss)* | $-146.40MM | $-162.86MM | $-146.41MM |
| Stockholders Equity | $1,152.32MM | $1,056.08MM | $966.90MM |
| Inventory | $1.11MM | $0.00MM | $6.34MM |
| Assets | $1,488.09MM | $1,360.55MM | $1,356.95MM |
| Operating Cash Flow | $-43.88MM | $-108.56MM | $-131.29MM |
| Capital expenditure | $77.51MM | $78.40MM | $42.77MM |
| Investing Cash Flow | $-221.11MM | $121.41MM | $87.75MM |
| Financing Cash Flow | $10.36MM | $12.77MM | $14.08MM |
| Earnings Per Share** | $-0.51 | $-0.55 | $-0.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.